AbbVie Inc (ABBV)vsNephros Inc (NEPH)
ABBV
AbbVie Inc
$257.12
+0.83%
HEALTHCARE · Cap: $454.36B
NEPH
Nephros Inc
$4.47
-1.11%
HEALTHCARE · Cap: $44.09M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 310613% more annual revenue ($64.39B vs $20.72M). ABBV leads profitability with a 9.8% profit margin vs 8.4%. NEPH trades at a lower P/E of 25.4x. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
NEPH
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$257.12
$105.30 premium
Margin of Safety
+12.6%
Fair Value
$4.62
Current Price
$4.47
$0.15 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 36.2% year-over-year
Earnings expanding 450.0% YoY
Conservative balance sheet, low leverage
Strong operational efficiency at 20.2%
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Moderate valuation
Smaller company, higher risk/reward
ROE of 7.3% — below average capital efficiency
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : NEPH
The strongest argument for NEPH centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 36.2% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : NEPH
The primary concerns for NEPH are P/E Ratio, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while NEPH is a hypergrowth play — different risk/reward profiles.
NEPH carries more volatility with a beta of 1.56 — expect wider price swings.
NEPH is growing revenue faster at 36.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 58/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Nephros Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Nephros, Inc., a commercial stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company is headquartered in South Orange, New Jersey.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?